2/2/2021 * Q4 sales, EBIT miss expectations * Firm expects 2-6% sales growth this year * CFO sees return to growth in bioethanol market in Q2 (Adds share reaction, CFO comment, analyst comment, background) By Nikolaj Skydsgaard COPENHAGEN, Feb 2 (Reuters) - Novozymes shares fell 4% on Tuesday after the enzyme maker missed fourth-quarter sales and earnings expectations, but said it expected sales to bounce back in 2021. Sales were flat in 2020, short of the 5% annual growth target set out in 2019 for 2020 through 2022. The company expects organic sales to grow 2-6% in 2021. "Despite the prevai...